Dimension to End Development of DTX101 as Gene Therapy for Hemophilia B – Hemophilia News Today
Hemophilia News Today |
Dimension to End Development of DTX101 as Gene Therapy for Hemophilia B
Hemophilia News Today Dimension Therapeutics will discontinue clinical development of DTX101, a gene therapy intended to treat moderate/severe-to-severe hemophilia B. The decision comes after a review of data from a Phase 1/2 clinical trial (NCT02618915), which assessed … |
